NASDAQ:TRIB
Trinity Biotech plc Stock News
$2.08
-0.330 (-13.69%)
At Close: Jun 25, 2024
Trinity Biotech to Begin European Pre-Pivotal Trial to Optimize its CGM Sensor
07:00am, Monday, 24'th Jun 2024
DUBLIN, June 24, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) a commercial stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable
Trinity Biotech Attending 84th Scientific Sessions of the American Diabetes Association
09:10am, Monday, 10'th Jun 2024
DUBLIN, June 10, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) (the “Company”), a commercial stage biotechnology company focused on diabetes management solutions and human diagnostic
Trinity Biotech Launches its Continuous Glucose Monitoring Microsite to Showcase its Innovative & Differentiated Technology
04:00am, Monday, 03'rd Jun 2024
DUBLIN, June 03, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) a commercial stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable
Trinity Biotech plc (TRIB) Q1 2024 Earnings Call Transcript
06:44pm, Thursday, 23'rd May 2024
Trinity Biotech plc (NASDAQ:TRIB ) Q1 2024 Results Conference Call May 23, 2024 8:30 AM ET Company Participants Eric Ribner - Investor Relations John Gillard - Chief Executive Officer Des Fitzgerald -
Trinity Biotech Announces Q1 2024 Financial Results and Reiterates Guidance
08:00am, Thursday, 23'rd May 2024
-Business performance on track to achieve approximately $20 million of annualized run-rate EBITDASO 1 on annualized revenues of approximately $75 million by Q2 2025-
Trinity Biotech plc to Announce Q1 2024 Financial Results
04:05pm, Tuesday, 21'st May 2024
DUBLIN, Ireland, May 21, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) (the “Company”), a commercial stage biotechnology company focused on diabetes management solutions and human di
Trinity Biotech Announces Strategic Collaboration with Medical Artificial Intelligence Company PulseAI
09:18am, Thursday, 16'th May 2024
DUBLIN, Ireland, May 16, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) a commercial stage biotechnology company focused on human diagnostics and diabetes management solutions, including
Trinity Biotech Announces Increased Orders for TrinScreen HIV and Raises Guidance for 2024 TrinScreen HIV Sales
11:42am, Monday, 13'th May 2024
DUBLIN, Ireland, May 13, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) a commercial stage biotechnology company focused on human diagnostics and diabetes management solutions, including
Trinity Biotech Welcomes Avinash Kale as Continuous Glucose Monitor Programme Director to Advance Innovation and Development
10:36am, Wednesday, 08'th May 2024
DUBLIN, Ireland, May 08, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) a commercial stage biotechnology company focused on human diagnostics and diabetes management solutions, including
Trinity Biotech plc (TRIB) Q4 2023 Earnings Call Transcript
03:03pm, Thursday, 04'th Apr 2024
Trinity Biotech plc (NASDAQ:TRIB ) Q4 2023 Earnings Conference Call April 4, 2024 8:00 AM ET Company Participants John Gillard - Chief Executive Officer Des Fitzgerald - Chief Financial Officer Eric R
Trinity Biotech Announces Fourth Quarter and Fiscal Year 2023 Financial Results & Business Updates
07:30am, Thursday, 04'th Apr 2024
DUBLIN, Ireland, April 04, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial stage biotechnology company focused on diabetes management solutions and human diagnostics, includi
Trinity Biotech plc to Announce Q4 and Fiscal Year 2023 Financial Results
06:39pm, Thursday, 28'th Mar 2024
DUBLIN, Ireland, March 28, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) (the “Company”), a leading developer and manufacturer of diagnostic solutions for the point-of-care and clini
Trinity Biotech Regains Compliance with Nasdaq Minimum Closing Bid Price Rule
10:03am, Friday, 08'th Mar 2024
DUBLIN, Ireland, March 08, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech Plc. (NASDAQ: TRIB) (the “Company”) today reported the receipt of a formal notification from The Nasdaq Stock Market LLC ("Nasda
Trinity Biotech Plc Finalizes Effective Date of ADS Ratio Change
12:34pm, Thursday, 15'th Feb 2024
DUBLIN, Ireland, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech Plc.(NASDAQ: TRIB) (the “Company”) today announced that it has finalized the effective date of its ratio change of its American d
Trinity Biotech Plc Announces Plan to Implement ADS Ratio Change
09:00am, Tuesday, 13'th Feb 2024
DUBLIN, Ireland, Feb. 13, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech Plc.(NASDAQ: TRIB) (the “Company”) today announced that it plans to change the ratio of the American depositary shares (“ADSs�